167 related articles for article (PubMed ID: 9403021)
21. Pamidronate treatment in patients with tumor-associated hypercalcemia: pharmacological effects and pharmacokinetics.
Oiso Y; Tomita A; Hasegawa H; Ariyoshi Y; Niinomi M; Yamamoto M; Takano T; Sakiyama N
Endocr J; 1994 Dec; 41(6):655-61. PubMed ID: 7704089
[TBL] [Abstract][Full Text] [Related]
22. Immobilization hypercalcemia treatment with pamidronate disodium after spinal cord injury.
Massagli TL; Cardenas DD
Arch Phys Med Rehabil; 1999 Sep; 80(9):998-1000. PubMed ID: 10488998
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and Safety of Intravenous Pamidronate for Parathyroid Hormone-dependent Hypercalcemia in Hospitalized Patients.
Rosenblum RC; Twito O; Barzilay-Yoseph L; Ramaty E; Klein N; Rotman-Pikielny P
J Clin Endocrinol Metab; 2021 Oct; 106(11):e4593-e4602. PubMed ID: 34157125
[TBL] [Abstract][Full Text] [Related]
24. Significance of plasma PTH-rp in patients with hypercalcemia of malignancy treated with bisphosphonate.
Wimalawansa SJ
Cancer; 1994 Apr; 73(8):2223-30. PubMed ID: 8156530
[TBL] [Abstract][Full Text] [Related]
25. Pamidronate treatment of hypercalcemia caused by vitamin D toxicity.
Chatterjee M; Speiser PW
J Pediatr Endocrinol Metab; 2007 Nov; 20(11):1241-8. PubMed ID: 18183797
[TBL] [Abstract][Full Text] [Related]
26. Childhood cancer and hypercalcemia: report of a case treated with pamidronate.
Kutluk MT; Hazar V; Akyüz C; Varan A; Büyükpamukçu M
J Pediatr; 1997 May; 130(5):828-31. PubMed ID: 9152297
[TBL] [Abstract][Full Text] [Related]
27. Safety of pamidronate in patients with renal failure and hypercalcemia.
Machado CE; Flombaum CD
Clin Nephrol; 1996 Mar; 45(3):175-9. PubMed ID: 8706358
[TBL] [Abstract][Full Text] [Related]
28. Use of bisphosphonates for resistant hypercalcemia in children with acute lymphoblastic leukemia: report of two cases and review of the literature.
Andiran N; Alikaşifoğlu A; Küpeli S; Yetgin S
Turk J Pediatr; 2006; 48(3):248-52. PubMed ID: 17172070
[TBL] [Abstract][Full Text] [Related]
29. Use of disodium pamidronate in children with hypercalcemia awaiting liver transplantation.
Attard TM; Dhawan A; Kaufman SS; Collier DS; Langnas AN
Pediatr Transplant; 1998 May; 2(2):157-9. PubMed ID: 10082449
[TBL] [Abstract][Full Text] [Related]
30. Dose-response in the treatment of hypercalcemia of malignancy by a single infusion of the bisphosphonate AHPrBP.
Thiébaud D; Jaeger P; Jacquet AF; Burckhardt P
J Clin Oncol; 1988 May; 6(5):762-8. PubMed ID: 3367184
[TBL] [Abstract][Full Text] [Related]
31. The use of pamidronate in three children with renal disease.
Sellers E; Sharma A; Rodd C
Pediatr Nephrol; 1998 Nov; 12(9):778-81. PubMed ID: 9874327
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of ibandronate in the treatment of hypercalcemia of malignancy: a randomized multicentric comparison to pamidronate.
Pecherstorfer M; Steinhauer EU; Rizzoli R; Wetterwald M; Bergström B
Support Care Cancer; 2003 Aug; 11(8):539-47. PubMed ID: 12783289
[TBL] [Abstract][Full Text] [Related]
33. Immobilization hypercalcemia in incomplete paraplegia: successful treatment with pamidronate.
Kedlaya D; Brandstater ME; Lee JK
Arch Phys Med Rehabil; 1998 Feb; 79(2):222-5. PubMed ID: 9474008
[TBL] [Abstract][Full Text] [Related]
34. Uses and effectiveness of pamidronate disodium for treatment of dogs and cats with hypercalcemia.
Hostutler RA; Chew DJ; Jaeger JQ; Klein S; Henderson D; DiBartola SP
J Vet Intern Med; 2005; 19(1):29-33. PubMed ID: 15715044
[TBL] [Abstract][Full Text] [Related]
35. Bisphosphonate Versus Bisphosphonate and Calcitonin for the Treatment of Moderate to Severe Hypercalcemia of Malignancy.
Khan AA; Gurnani PK; Peksa GD; Whittier WL; DeMott JM
Ann Pharmacother; 2021 Mar; 55(3):277-285. PubMed ID: 32885992
[TBL] [Abstract][Full Text] [Related]
36. Renal phosphate threshold and response to pamidronate in humoral hypercalcaemia of malignancy.
Gurney H; Kefford R; Stuart-Harris R
Lancet; 1989 Jul; 2(8657):241-4. PubMed ID: 2569054
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of new bone resorption markers in a randomized comparison of pamidronate or clodronate for hypercalcemia of malignancy.
Vinholes J; Guo CY; Purohit OP; Eastell R; Coleman RE
J Clin Oncol; 1997 Jan; 15(1):131-8. PubMed ID: 8996134
[TBL] [Abstract][Full Text] [Related]
38. A multicenter and open label clinical trial of zoledronic acid 4 mg in patients with hypercalcemia of malignancy.
Kawada K; Minami H; Okabe K; Watanabe T; Inoue K; Sawamura M; Yagi Y; Sasaki T; Takashima S
Jpn J Clin Oncol; 2005 Jan; 35(1):28-33. PubMed ID: 15681601
[TBL] [Abstract][Full Text] [Related]
39. Severe Hypercalcemia in a Child With Acute Lymphoblastic Leukemia Relapse: Successful Management With Combination of Calcitonin and Bisphosphonate.
Tagiyev A; Demirbilek H; Tavil B; Buyukyilmaz G; Gumruk F; Cetin M
J Pediatr Hematol Oncol; 2016 Apr; 38(3):232-4. PubMed ID: 26907650
[TBL] [Abstract][Full Text] [Related]
40. Use of pamidronate in the management of acute cancer-related hypercalcemia in children.
Kutluk T; Akyüz C; Yalçin B; Varan A; Büyükpamuküçu M
Med Pediatr Oncol; 1998 Jul; 31(1):39. PubMed ID: 9607431
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
